We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+44.97%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.38B
AUM Growth
+$1.14B
Cap. Flow
+$493M
Cap. Flow %
14.6%
Top 10 Hldgs %
62.24%
Holding
58
New
13
Increased
11
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$180M
2
NVTA
Invitae Corporation
NVTA
+$156M
3
BLFS icon
BioLife Solutions
BLFS
+$54.6M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$24.7M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$119M
2
AMRS
Amyris Inc.
AMRS
+$23.6M
3
ILMN icon
Illumina
ILMN
+$9.27M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$7.69M
5
LEGN icon
Legend Biotech
LEGN
+$4.31M

Sector Composition

Rank Sector Weight
1 Healthcare 84.21%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
51
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.17M 0.06%
+50,000
New +$2.47M
CCCC icon
52
C4 Therapeutics
CCCC
$387M
$1.32M 0.04%
+40,000
New +$1.16M
ILMN icon
53
Illumina
ILMN
$29.9B
– –
-30,840
Closed -$9.27M
LEGN icon
54
Legend Biotech
LEGN
$3.68B
– –
-139,661
Closed -$4.31M
DCPH
55
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-65,000
Closed -$3.33M
ORTX
56
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-187,000
Closed -$7.69M
AMRS
57
DELISTED
Amyris Inc.
AMRS
– –
-7,390,000
Closed -$23.6M
MYOK
58
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-870,000
Closed -$119M
1 2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Casdin Capital held 58 positions worth $3.38B, up 51% from $2.23B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Casdin Capital deployed $493M of net new capital in Q4 2020, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Exact Sciences: 1,485,149 shares worth $197M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $2.26M trimmed.

  • Casdin Capital's largest Q4 2020 buy was Exact Sciences: 1,485,149 shares worth $197M.
  • Casdin Capital added most to Invitae Corporation in Q4 2020, an estimated $156M increase.
  • Casdin Capital's biggest Q4 2020 reduction was Fulcrum Therapeutics, cutting an estimated $2.26M.
  • Casdin Capital fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $119M.
  • Casdin Capital's ten largest holdings make up 62% of its $3.38B portfolio in Q4 2020.
  • Casdin Capital opened 13 new positions and closed 6 in Q4 2020.
  • Casdin Capital's portfolio value rose 51% quarter-over-quarter to $3.38B.

Based on Casdin Capital's 13F filing for Q4 2020, filed 16 Feb 2021.